|
The following stocks are the leading risers among London Main Market small-caps on Monday. ---------- SMALL-CAP - WINNERS ---------- Saga PLC, up 8.1% at 316.75 pence, 12-month range 111.6p-316.75p. The cruise operator’s shares have continued to rise since Thursday, when UK hedge fund Kernow said its shares could increase by more than 400%. ---------- Mears Group PLC, up 4.7% at 371.75p, 12-month range 311.5p-417.5p. The provider of housing services to the UK public and regulated sectors says it has traded strongly in the second half to date. It expects adjusted pretax profit for 2025 to be at the top end of its market guidance issued in August, when it reiterated that the figure would be ‘modestly ahead of market expectations’. Back in June, it set a minimum target of £54 million, higher than the company-cited consensus of £50.9 million. ---------- PureTech Health PLC, up 3.1% at 125.8p, 12-month range 103p-170p. Completes its end-of-phase 2 meeting with the US Food & Drug Administration to develop deupirfenidone for the treatment of idiopathic pulmonary fibrosis. Says the meeting was supported by results from the phase 2b ELEVATE IPF trial, in which participants treated with deupirfenidone experienced a slower rate of lung function decline versus those who were treated with pirfenidone or placebo. Its founded entity Celea Therapeutics expects to finalise financing in early 2026, to support the initiation of the phase 3 SURPASS-IPF trial in the first half of the year. The phase 3 study will compare deupirfenidone to pirfenidone in adults with idiopathic pulmonary fibrosis who are not on background therapy. PureTech adds that based on FDA feedback, it believes that successful results from the phase 3 trial could complete the data package required to support potential registration of deupirfenidone through a streamlined regulatory pathway. ---------- Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
